Tamer Akel1, James Lafferty2. 1. Department of Internal Medicine, Staten Island University Hospital, Staten Island, NY, USA. 2. Department of Cardiology, Staten Island University Hospital, NY, USA.
Abstract
BACKGROUND: Atrial fibrillation is a common cardiac arrhythmia with increasing prevalence in the aging population. It is a major cause of emergency department visits worldwide. Vernakalant, a relatively new antiarrhythmic drug with selectively preferential effects on the atrial tissue is currently used in many European countries for the termination of recent-onset atrial fibrillation. Presently, the drug is still not approved by the United States Food and Drug Administration due to safety concerns. We evaluate the efficacy and safety of vernakalant for the conversion of recent-onset atrial fibrillation or atrial flutter into normal sinus rhythm (NSR). METHODS: PubMed/MEDLINE (1993-2017), the Cochrane Central Register of Controlled Trials (2000-2017), and reference lists of relevant articles were searched for randomized controlled trials (RCTs) comparing vernakalant to a control drug and extracted subsequently. RESULTS: Nine RCTs were identified and included in the meta-analysis. Pooled analysis of events extracted for a total of 1421 patients with recent-onset atrial fibrillation showed a statistically significant increase in cardioversion within 90 minutes from drug infusion (Relative Risk [RR], 6.61; 95% Confidence Interval [CI], 2.78 - 15.71; p < .00001). In terms of adverse events, vernakalant was considered safe in comparison to control drugs (RR, 0.80; 95% CI, 0.61-1.05; p = .11). CONCLUSION: Vernakalant is effective for rapid conversion of recent-onset atrial fibrillation into NSR. However, although it showed a safe profile in terms of side effects in this analysis, we are still hesitant about this conclusion and few safety issues should be addressed within specific patients' subgroups.
BACKGROUND:Atrial fibrillation is a common cardiac arrhythmia with increasing prevalence in the aging population. It is a major cause of emergency department visits worldwide. Vernakalant, a relatively new antiarrhythmic drug with selectively preferential effects on the atrial tissue is currently used in many European countries for the termination of recent-onset atrial fibrillation. Presently, the drug is still not approved by the United States Food and Drug Administration due to safety concerns. We evaluate the efficacy and safety of vernakalant for the conversion of recent-onset atrial fibrillation or atrial flutter into normal sinus rhythm (NSR). METHODS: PubMed/MEDLINE (1993-2017), the Cochrane Central Register of Controlled Trials (2000-2017), and reference lists of relevant articles were searched for randomized controlled trials (RCTs) comparing vernakalant to a control drug and extracted subsequently. RESULTS: Nine RCTs were identified and included in the meta-analysis. Pooled analysis of events extracted for a total of 1421 patients with recent-onset atrial fibrillation showed a statistically significant increase in cardioversion within 90 minutes from drug infusion (Relative Risk [RR], 6.61; 95% Confidence Interval [CI], 2.78 - 15.71; p < .00001). In terms of adverse events, vernakalant was considered safe in comparison to control drugs (RR, 0.80; 95% CI, 0.61-1.05; p = .11). CONCLUSION:Vernakalant is effective for rapid conversion of recent-onset atrial fibrillation into NSR. However, although it showed a safe profile in terms of side effects in this analysis, we are still hesitant about this conclusion and few safety issues should be addressed within specific patients' subgroups.
Authors: Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy Journal: Circulation Date: 2014-03-28 Impact factor: 29.690
Authors: Juan Cosin-Sales; Armando Loscos; Ana Peiró; M Rosa Sorando; Francisco Buendía; Luis Ruescas Journal: Rev Esp Cardiol (Engl Ed) Date: 2016-05-04
Authors: Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas Journal: Eur Heart J Date: 2016-08-27 Impact factor: 29.983
Authors: A John Camm; Alessandro Capucci; Stefan H Hohnloser; Christian Torp-Pedersen; Isabelle C Van Gelder; Brian Mangal; Gregory Beatch Journal: J Am Coll Cardiol Date: 2011-01-18 Impact factor: 24.094
Authors: A John Camm; Egon Toft; Christian Torp-Pedersen; Pugazhendhi Vijayaraman; Steen Juul-Moller; John Ip; Gregory N Beatch; Garth Dickinson; D George Wyse Journal: Europace Date: 2012-01-29 Impact factor: 5.214
Authors: Denis Roy; Craig M Pratt; Christian Torp-Pedersen; D George Wyse; Egon Toft; Steen Juul-Moller; Tonny Nielsen; S Lind Rasmussen; Ian G Stiell; Benoit Coutu; John H Ip; Edward L C Pritchett; A John Camm Journal: Circulation Date: 2008-03-10 Impact factor: 29.690
Authors: Paul Dorian; Arnold Pinter; Iqwal Mangat; Victoria Korley; Suzan S Cvitkovic; Gregory N Beatch Journal: J Cardiovasc Pharmacol Date: 2007-07 Impact factor: 3.105
Authors: Alexander Simon; Jan Niederdoeckl; Ekaterini Skyllouriotis; Nikola Schuetz; Harald Herkner; Christoph Weiser; Anton N Laggner; Hans Domanovits; Alexander O Spiel Journal: Europace Date: 2017-02-01 Impact factor: 5.214
Authors: William F McIntyre; Jeff S Healey; Akash K Bhatnagar; Patrick Wang; Jacob A Gordon; Adrian Baranchuk; Bishoy Deif; Richard P Whitlock; Émilie P Belley-Côté Journal: Europace Date: 2019-08-01 Impact factor: 5.214